Exited: CF&E Investments Group has successfully exited its investment in DayTwo

CF&E Investments Group had generated significant returns on its initial investment. DayTwo, a healthtech startup, gained attention for its microbiome-based platform, which provides personalized nutrition recommendations, particularly targeting diabetes management. The company's approach, which leverages AI to analyze gut microbiomes, has positioned it as an innovator in the food-as-medicine sector.

Despite challenges and a major restructuring effort in 2023 due to market competition and internal shifts, DayTwo's pioneering technology and data-driven approach made it an attractive acquisition target. CF&E Investments likely benefited from the growing interest in digital health solutions and precision medicine, securing favorable exit terms.